Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.51 |
| ▸ | HTR7 | P34969 | 3/20 | 0.46 |
| ▸ | NOS3 | P29474 | 9/20 | 0.44 |
| ▸ | NOS1 | P29475 | 9/20 | 0.44 |
| ▸ | NOS2 | P35228 | 6/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.42 |
| ▸ | HTR1B | P28222 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6745791 | 1.00 | HTR6 (0.51) | HTR6HTR7NOS3NOS1NOS2 | |
| SCHEMBL6744609 | 0.91 | HTR6 (0.47) | HTR6HTR7NOS3NOS1NOS2 | |
| SCHEMBL6744614 | 0.91 | HTR6 (0.47) | HTR6HTR7NOS3NOS1NOS2 | |
| SCHEMBL6775704 | 0.90 | HTR6 (0.43) | HTR6HTR7NOS3NOS1NOS2 | |
| SCHEMBL6742324 | 0.80 | HTR6 (0.45) | HTR6NOS3NOS1HTR1DHTR1B | |
| SCHEMBL6948541 | 0.79 | HTR6 (0.44) | HTR6NOS3NOS1NOS2HTR1D | |
| SCHEMBL6948549 | 0.79 | HTR6 (0.44) | HTR6NOS3NOS1NOS2HTR1D | |
| SCHEMBL6745125 | 0.77 | HTR6 (0.43) | HTR6NOS3NOS1HTR1DHTR1B | |
| SCHEMBL6740169 | 0.76 | HTR6 (0.42) | HTR6HTR1DHTR1B | |
| SCHEMBL6739874 | 0.76 | HTR6 (0.42) | HTR6HTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040167158-A1 | Heterocyclic compounds for the treatment of migraine | NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 2004-08-26 | — | — | US | disclosed |
| US-6716837-B1 | INDOLE AND INDAZOLE COMPOUNDS | NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 2004-04-06 | — | — | US | disclosed |
| EP-1196380-A2 | INDOLES AND INDAZOLES FOR THE TREATMENT OF MIGRAINE | NPS Allelix Corp. (CA) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001005758-A2 | INDOLES AND INDAZOLES FOR THE TREATMENT OF MIGRAINE | NPS ALLELIX CORP. (CA) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167158-A1 | Heterocyclic compounds for the treatment of migraine | SCN7A, CNR2, HTR7 | HTR6 237/4885HTR7 3/4885NOS3 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.